Description

Eribulin is a synthetic macrocyclic ketone analog of the marine natural product halichondrin B, developed as a potent antineoplastic agent. Its primary value lies in its unique mechanism of action, inhibiting microtubule dynamics, which makes it a critical therapeutic option for specific, difficult-to-treat cancers. This active pharmaceutical ingredient (API) is essential for pharmaceutical manufacturers and research institutions focused on oncology drug development and production, particularly for metastatic breast cancer and liposarcoma.

Application

• Oncology Pharmaceutical Manufacturing: As the active pharmaceutical ingredient (API) in injectable formulations for the treatment of metastatic breast cancer.
• Liposarcoma Treatment: Serves as the key therapeutic component in medicines approved for advanced or metastatic liposarcoma.
• Clinical Research & Development: Used in preclinical and clinical studies to investigate new cancer treatment protocols and combination therapies.
• Anticancer Mechanism Studies: A vital tool in biochemical and pharmacological research for studying microtubule dynamics and mitosis inhibition.
• Reference Standard: Employed as a high-purity analytical standard in quality control laboratories for drug testing and verification.
• Drug Discovery: Acts as a lead compound or benchmark in the discovery and development of novel antimitotic agents.

Basic Information

Product Name	Eribulin
CAS No.	253128-41-5
Molecular Formula	C40H59NO11
Molecular Weight	729.90 g/mol
Synonyms	Eribulin Mesylate; Halaven; ER-086526; E7389; B1939 mesylate; (2S,3aS,4R,5aS,5bS,9S,11aR,12aR,12bS)-9-{[(2R)-2-Amino-2-methylpropyl]oxy}-4,12a-bis(benzyloxy)-5b-{[(2R)-3,3-dimethyloxiran-2-yl]methoxy}-2,5a,8,8,11a,12b-hexamethyl-1,3,3a,4,5,5a,5b,6,9,10,11,11a,12,12a,12b,13,14,14a-octadecahydrocyclopenta[7,8]phenanthro[2,3-d]oxepine-2-carboxylic acid methyl ester
EINECS	Contact for details

Quality Control

Our Eribulin is manufactured under strict quality systems to meet the rigorous standards required for pharmaceutical active ingredients. Each batch is subjected to comprehensive analytical testing, including identity confirmation, purity assay, and impurity profiling via advanced techniques like HPLC and mass spectrometry. Certificates of Analysis (COA) are provided, detailing compliance with in-house specifications aligned with ICH guidelines. We support cGMP (current Good Manufacturing Practice) standards to ensure consistency and reliability for our global clientele in regulated markets.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C) or as specified on the label. Due to its hygroscopic nature, the container must be kept tightly sealed in a dry environment to prevent moisture absorption. For long-term storage, consider conditions under an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Related Substances (HPLC)	Total impurities ≤2.0% Any single impurity ≤0.5%
Residual Solvents (GC)	Complies with ICH Q3C
Water Content (KF)	≤1.0%
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.